Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark, Sun to Sell Generic Version of Trileptal in US (India)

This article was originally published in PharmAsia News

Executive Summary

Glenmark Pharmaceuticals and Sun Pharmaceutical Industries have received approval to market a generic version of Trileptal. The drug, also known as oxcarbazepine, is an epilepsy treatment manufactured by Novartis. Last year, Novartis saw about $643 million in sales from the drug, just in the U.S. Glenmark and Sun Pharma, two of India's biggest drug manufacturers, will share the exclusive marketing rights for the generic Trileptal for 180-days. However, they may have to end up sharing the rights during this time with U.S.-based generics company Roxane Laboratories. (Click here for more
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC065689

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel